HOST Therabiomics

HOST Therabiomics is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about HOST Therabiomics. We are a global microbiome-based therapeutics company that has been working for more than a decade to apply our understanding of the human host-microbiome interaction to modify, treat, and prevent disease. Our therapeutic development reaches beyond the microbiome to influence or intervene in disease by targeting the broader set of interactions that occur at the host+biome intersection. Historically, most microbiome-based drug development has focused on introducing specific beneficial bacterial species or other compounds to the gut, mouth, or skin to try and restore health. Many companies using this approach have had limited success in clinical trials, and challenges remain to identify and validate the underlying mechanisms of how these drugs may work and the impact on disease. Our targeted, evidence-based strategy for developing microbiome-based therapeutics applies our understanding of distinct interactions between a human host and the “biome”. HOST Therabiomics’ “host+biome” approach uses a biotechnology platform to first identify and target key ways that can be used to optimize the biome to promote positive therapeutic responses from the host. Then, through the development of proprietary enzyme systems, create target-specific compounds that when exposed to the biome modulate the composition of the biome and/or interact directly with the host to ameliorate diseases and symptoms at these points of interaction.